Department of Pharmacy, 864 Radboud University Nijmegen Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, the Netherlands.
Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1151-60. doi: 10.1517/17425255.2010.513383.
Raltegravir is the first HIV-integrase inhibitor licensed by the FDA.
A PubMed search was conducted for all published reports up to 1 May 2010 related to raltegravir pharmacokinetics, pharmacology, drug-drug interactions and clinical studies in HIV-infected patients. Also included in this review are the updated European and US Prescriber's Information (European Medicines Agency and the FDA) and abstracts from recent international scientific meetings.
After reading the review, a thorough insight in raltegravir pharmacokinetics and pharmacology will be obtained, as well as an up-to-date overview of all published drug-drug interaction studies. Furthermore, one should be able to make an evidence-based opinion on the drug's clinical efficacy and tolerability.
Raltegravir is a welcome addition to the antiretroviral drug armamentarium due to its good tolerability, low potential for drug-drug interactions and good clinical efficacy in both treatment-naive and -experienced patients.
拉替拉韦是第一个获得美国食品药品监督管理局批准的 HIV 整合酶抑制剂。
对截至 2010 年 5 月 1 日所有与拉替拉韦药代动力学、药理学、药物相互作用和 HIV 感染患者临床研究相关的已发表报告进行了 PubMed 检索。此外，还包括更新后的欧洲和美国处方信息（欧洲药品管理局和美国食品药品监督管理局）以及最近国际科学会议的摘要。
阅读本综述后，读者将深入了解拉替拉韦的药代动力学和药理学，并全面了解所有已发表的药物相互作用研究。此外，读者应该能够对该药物的临床疗效和耐受性做出基于证据的判断。
拉替拉韦由于其良好的耐受性、低药物相互作用潜力以及在初治和经治患者中的良好临床疗效，是抗逆转录病毒药物治疗的一个可喜的补充。
